“高价药”的成因及其治理策略研究——基于德、日药价管理经验  

Research on the Cause of"High Price Medicine"and Its Treatment Strategy:Based on Experience in Drug Price Management in Germany and Japan

作　　者：张雪强 潘梦超 ZHANG Xue-qiang;PAN Meng-chao(Anhui University of Finance&Economics,Bengbu 233030,China)

机构地区：[1]安徽财经大学,蚌埠233030

出　　处：《价值工程》2021年第8期237-239,共3页Value Engineering

摘　　要：生命诚可贵,但“看病难”“看病贵”问题却成了人们就医的掣肘。本文在了解德国和日本针对药价管理及调整的经验后,从药品价格的定价机制、药品流通及交易环节和“以药养医”机制桎梏三个视角来探寻国内“高价药”的根源,并针对该问题提出转变定价理念,综合考量药品的成本与疗效、加快普及“两票制”和药品价格可追溯机制、全面推进以“国家组织、大量采购”为特点的公立医院药品集中采购制度、药价长效动态调整,加快新药研发以及完善医疗机构绩效工资制度,破解“以药养医”机制的相关建议。Life is precious,but the problem of"difficult to see a doctor"and"expensive to see a doctor"has become a constraint for people to go to a doctor.After understanding the experience of Germany and Japan in the management and adjustment of drug prices,this paper explores the root causes of domestic"high-priced drugs"from three perspectives:the pricing mechanism of drug prices,drug circulation and transaction links,and the"support medicine with drugs"mechanism.In response to this problem,it puts forward related suggestions that changing the pricing concept,comprehensively considering the cost and efficacy of drugs,accelerating the popularization of the"two-vote system"and the traceability mechanism of drug prices,comprehensively promoting the centralized drug procurement system in public hospitals with the characteristics of"national organization and mass procurement"and the long-term dynamic adjustment of drug prices,accelerating the development of new drugs and improving the performance wage system in medical institutions,so as to crack the mechanism of"support medicine with drugs".

关 键 词：药价管理 定价理念 两票制 可追溯机制 以药养医 

分 类 号：F763[经济管理—产业经济]